Study registration: *
Publication Giansante C, Acta Biomed, 2021
Dates: 2020-12-27 to 2021-04-30
Funding: Not reported/unclear
Conflict of interest: no COI (Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article )

Methods

Study design:Cohort
Description of participants: The staff of the Bologna Health Trust, Emilia Romagna Region, Northern Italy.
Inclusion criteria:
  • All staff of the Bologna Health Trust between December 27, 2020 and April 30, 2021

Exclusion criteria:
  • Previously documented SARS-CoV-2 infection
  • vaccinated with non-mRNA vaccines
  • zero follow-up days after vaccination

Follow-up duration (months): 4.13
Vaccines:
  • 1 or 2 doses of BNT162b2 or mRNA-1273
Variant description :
Variant name: Alpha
Evidence: Indirect evidence (prevalence of variant in the population: 36% to 78%)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: NR
Data accessibility: Elisa Stivanello, MD: E-mail: elisa.stivanello@ausl.bologna.it
General comment Concerns about uncontrolled confounding; factors such as socio-economic status and comorbidities were not adjusted for.